Bli medlem
Bli medlem

Du är här

2022-11-10

Camurus AB: Camurus' Interim Report Third Quarter 2022

"The third quarter was financially Camurus' best quarter to date"

Third quarter summary

July - September

  • Total revenues amounted to SEK 241 (154) million, an increase of 57% (45% at CER[1]), 

whereof product sales were SEK 241 (152) million, an increase of 58% (47% at CER)

  • Operating result was SEK 41 (-6) million, an increase of SEK 48 million
  • Cash position at the end of the quarter was SEK 520 (426) million, an increase of SEK 93 million
  • Number of patients treated with Buvidal[®] at the end of the quarter estimated at 32,000
  • Total number of Buvidal units sold passed one million
  • Buvidal approved in Egypt and Saudi Arabia as the first approved maintenance treatment of opioid dependence
  • First patient dosed in Phase 2b study of CAM2029 in polycystic liver disease
  • Five-year vision for innovation and growth presented at our Capital Markets and R&D Day

January - September

  • Total revenues amounted to SEK 688 (418) million, an increase of 65% (55% at CER[1]), 

whereof product sales were SEK 668 (413) million, an increase of 62% (53% at CER)

  • Operating result was SEK 53 (-92) million, an increase of SEK 146 million[ ]

Events after the quarter

  • Recruitment completed in Phase 3 randomized control efficacy study of CAM2029 in acromegaly

Outlook for full year 2022

  • Operating result guidance raised from SEK -20 to 40 million to SEK 40 to 70 million[2]

1) At constant exchange rates in January 2022
2) Excluding milestone payments related to a potential approval of Brixadi™ in the US

Financial summary third quarter 2022

  • Total Revenue SEK 241 (154) million 

- whereof product sales SEK 241 (152) million

  • OPEX SEK 184 (139) million
  • Operating result SEK 41 (-6) million
  • Result for the period SEK 35 (-6) million
  • Results per share, after dilution, of SEK 0.61 (-0.11)
  • Cash position SEK 520 (426) million

Fredrik Tiberg, President and CEO:
"In the third quarter 2022, we continued the path to sustainable profitability through growing Buvidal[®] sales and an increased positive operating result, which further consolidated our financial position. We continued the market expansion through new Buvidal regulatory and pricing approvals and advanced our registration and Phase 3 programs in chronic pain and rare diseases. The development programs were presented at our Capital Markets and R&D Day in September along with a five-year vision for growth and innovation."

Audiocast
Financial analysts and media are invited to attend a telephone conference and presentation of the results today at 2 pm (CET). The conference call can also be followed by a link on www.camurus.com or via external link: https://financialhearings.com/event/43985.

For more information:
Fredrik Tiberg, President and CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com

Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com

About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal[®] drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation and to the Securities Markets Act. The information was submitted for publication, through the agency of the chief executive officer, 07.00 AM (CET) on 10 November, 2022.

Författare Cision